Biofrontera Inc.
corporate_fare Company Profile
Biofrontera Inc. (NASDAQ:BFRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for BFRI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for BFRI spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Biofrontera Hit With Nasdaq Bid-Price Deficiency Notice, 180 Days to Reach $1.00
- Biofrontera Q3: Revenue Up 30% to $9.1M, But Going Concern and New Nasdaq Equity Deficiency
- Biofrontera Posts $9.1M Q3 Revenue but Swings to $6.4M Net Loss
- Biofrontera Seeks FDA Nod to Expand Ameluz Use to Full-Body Actinic Keratoses
- FDA Clears Ameluz for Skin Cancer, a First for Photodynamic Therapy
Financial Snapshot
Short Interest & Short Volume
1.30 days to coverFINRA reported short interest of 189,627 shares in BFRI as of the October 30, 2026 settlement, a 83.8% increase from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 32.0% of BFRI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BFRI, detected from its recent SEC filings · based on capital-structure filings through 2026-06-17.
Shareholder Meeting Results · Equity Incentive Plan Expanded
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →